Scientific and technical meetings at SPIE Photonics West

Staff from SpectraCure attended the SPIE’s conference BiOS – Photonics West in San Francisco in late January. Among other things, the partners of SpectraCure at the University of Pennsylvania presented results for the treatment of pleural cancer. The results confirmed that the real time-monitoring of optical properties, photosensitiser and oxygen supply during photodynamic treatment (PDT) is of great importance for efficient treatment results. This is fully in-line with SpectraCures IDOSE® platform, where these types of measurements are fundamental to how the treatment is performed. Note that SpectraCure is not involved in any way in the presented study.

Link to the presentations: http://spie.org/PWB/conferencedetails/photodynamic-therapy

SpectraCure also organised a meeting between the representatives of the three collaborating hospitals of the clinical Phase 1 study: Princess Margaret Cancer Centre in Toronto, the University of Pennsylvania Hospital in Philadelphia, and the University College London Hospital. During the meeting, the ongoing study was discussed and planning for the further study, which involves further treatment of patients in Toronto and the start of the study in Philadelphia and London in the spring.

During the technical exhibition which ran in conjunction with the scientific conference, SpectraCures representatives met with a number of prospective suppliers of components for the next-generation system. A first prototype of this system is planned to be completed in 2018.

Link: http://spie.org/conferences-and-exhibitions/photonics-west/photonics-west-exhibition

For further information, please contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46 (0) 70 815 21 90

SpectraCure in short

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer of the head and neck.

See pressrelease

SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects. 

Facebook Linkedin Envelope